Roche’s Ocrevus shows promise as a subcutaneous injection in phase 3 MS trial . The therapy is already approved for certain MS patients as a twice-yearly intravenous infusion . Roche has announced positive results from a late-stage study of Ocrevus (ocrelizumab) as a twice-yearly subcutaneous injection in patients with relapsing forms of multiple sclerosis (MS) or primary progressive MS. Over 2.8 million people worldwide are affected by MS, a disabling and unpredictable neurolo...